

PHAEOCHROMOCYTOMA (PCC)

Catecholamines are of clinical interest because they are diagnostic of phaeochromocytoma (PCC), a tumour of the chromaffin cells. Approximately 15% of tumours occur outside the adrenal glands (typically in the abdomen) and are called paragangliomas. Tumours may grow very large, but most are less than 10 cm. Approximately 10% are cancerous.

PCC is more common in women than in men. It occurs in early to mid-adulthood. 10% occur in children. PCC can be hereditary (Multiple Endocrine Neoplasia (MEN), Von Hippel-Lindau Syndrome, Neurofibromatosis) but may also develop sporadically.

The signs and symptoms are a consequence of over activity of the sympathetic nervous system:

Signs and symptoms of PCC


Headaches	Tremors
Sweating	Weakness
Fast heart beat	Abdominal pain
High blood pressure	Weight loss
Anxiety or panic attacks	Elevated blood glucose
Nausea	Sudden death

Not all patients experience all of these signs and symptoms. The most common presentation is headache, sweating and increased heart rate. Symptoms occur in discrete attacks at unpredictable intervals, and usually last 15 to 20 minutes. A doctor is more likely to consider PCC if the patient is young and has no other risk factors or habits that may cause these findings. Some people never develop symptoms. Up to 10% of cases are discovered incidentally.

Diagnosis

Familial history > Genetic testing		
24 Hour urine test		
Plasma catecholamines		
maging		
Biopsy	Y	

If a tumour is intermittently secreting catecholamines plasma tests may fail to detect any abnormality, whereas urine measurements are more likely to be elevated. Urine and plasma metanephrines (catecholamine metabolites) may be preferred as they are usually present in greater quantities than catecholamines in the urine, and can persist in the blood even when catecholamine levels have returned to normal.



Treatment

Surgery is the definitive treatment for PCC. Where tumours are confined to the adrenal gland and are benign there is a good prognosis. Recurrence rates average around 10%. Patients with recurrent tumours, tumours that spread or unable to be removed surgically, have a fair to poor outlook. Other treatments include alpha blockers to control blood pressure, tyrosine kinase inhibitors to inhibit the formation of hormones by the tumour or chemo therapy / radio therapy for malignant tumours.

Other applications

Biogenic amines may also be used for diagnosis of neuroblastoma, the most common cancer in infancy, or carcinoid tumour, a slow-growing type of neuroendocrine tumour.

Chiron now offer standards and standard mixes for catecholamines:

Part No.	Description	Cas No.	Concentration	Solvent	Volume
11646.10-K-ME	(+/-)-Metanephrine hydrochloride (3-O-Methylepinephrine HCl)	881-95-8	1000 μg base/mL	methanol	1 mL
12006.10-100-ME	(+/-)-Metanephrine- α , β , β -d3 hydrochloride	1085333-94-3	100 μg base/mL	methanol	1 mL
12007.10-100-ME	(+/-)-Metanephrine- α , β , β -d3 hydrochloride	1215507-88-2	100 μg base/mL	methanol	1 mL
11647.9-K-ME	(+/-)-Normetanephrine hydrochloride	1011-74-1	1000 μg base/mL	methanol	1 mL
11648.9-K-ME	(+/-)-Epinephrine hydrochloride (DL-Adrenaline HCl)	329-63-5	1000 μg base/mL	methanol	1 mL
11648.9-1G	(+/-)-Epinephrine hydrochloride (DL-Adrenaline HCl)	329-63-5	neat	neat	1 g
12563.9-100-ME	Epinephrine-d3 (Adrenaline-d3)	1189977-29-4	100 μg/mL	methanol	1 mL
11649.8-K-ME	(+/-)-Norepinephrine hydrochloride	55-27-6	1000 µg base/mL	methanol	1 mL
12009.9-100-ME	(+/-)-Normetanephrine- α , β , β -d3 hydrochloride	1085333-97-6	100 μg base/mL	methanol	1 mL
11650.9-K-ME	3-Methoxytyramine hydrochloride (3-MT HCI)	1477-68-5	1000 µg base/mL	methanol	1 mL
11650.9-10MG	3-Methoxytyramine hydrochloride (3-MT HCl)	1477-68-5	neat	neat	10 mg
12008.9-100-ME	3-Methoxytyramine-d4 hydrochloride (3-MT-d4 HCl)	1216788-76-9	100 μg base/mL	methanol	1 mL
12008.9-10MG	3-Methoxytyramine-d4 hydrochloride (3-MT-d4 HCl)	1216788-76-9	neat	neat	10 mg
11651.8-K-ME	Dopamine	51-61-6	1000 μg/mL	methanol with 5% 1 M HCl	1 mL
12564.8-100-ME	Dopamine-d4 hydrochloride	203633-19-6	100 μg base/mL	methanol	1 mL
10518.10-1G	Methyldopa Sesquihydrate (α-Methyl-L-DOPA)	555-30-6	neat	neat	1 g
14108.8-100-ME	3,4-Dihydroxyphenylacetic acid (DOPAC, Dopamine metabolite)	102-32-9	100 μg/mL	methanol	1 mL
14108.8-K-ME	3,4-Dihydroxyphenylacetic acid (DOPAC, Dopamine metabolite)	102-32-9	1000 μg/mL	methanol	1 mL
14108.8-10MG	3,4-Dihydroxyphenylacetic acid (DOPAC, Dopamine metabolite)	102-32-9	neat	neat	10 mg
14108.8-50MG	3,4-Dihydroxyphenylacetic acid (DOPAC, Dopamine metabolite)	102-32-9	neat	neat	50 mg
12085.9-100-ME	Homovanillic acid (HVA)	306-08-1	100 μg/mL	methanol	1 mL
12085.9-K-ME	Homovanillic acid (HVA)	306-08-1	1000 μg/mL	methanol	1 mL
12085.9-10MG	Homovanillic acid (HVA)	306-08-1	neat	neat	10 mg
12085.9-50MG	Homovanillic acid (HVA)	306-08-1	neat	neat	50 mg
14076.9-K-ME	Homovanillic acid-d5 (HVA-d5)	53587-32-9	1000 μg/mL	methanol	1 mL

Part No.	Description	Cas No.	Concentration	Solvent	Volume
11653.10-K-ME	5-Hydroxyindole-3-acetic acid (5-HIAA)	54-16-0	1000 μg/mL	methanol	1 mL
10983.10-K-ME	5-Hydroxyindole-3-acetic-2,2-d2 acid (5-HIAA-d2)	56209-31-5	1000 μg/mL	methanol	1 mL
10983.10-5MG	5-Hydroxyindole-3-acetic-2,2-d2 acid (5-HIAA-d2)	56209-31-5	neat	neat	5 mg
10983.10-10MG	5-Hydroxyindole-3-acetic-2,2-d2 acid (5-HIAA-d2)	56209-31-5	neat	neat	10 mg
13024.10-K-ME	5-Hydroxyindole-3-acetic-4,6,7-d3-2,2-d2 acid (5-HIAA-d5)	1219802-93-3	1000 μg/mL	methanol	1 mL
14077.10-K-ME	5-Hydroxytryptophol (5-HTOL)	154-02-9	1000 μg/mL	methanol	1 mL
14078.10-100-ME	5-Hydroxytryptophol-d4 (5-HTOL-d4)	66640-87-7	100 μg/mL	methanol	1 mL
12012.10-25MG	Serotonin hydrochloride (5-Hydroxytryptamine HCl, 5-HT HCl)	153-98-0	neat	neat	25 mg
10864.10-100-ME	Serotonin-13C2,15N hydrochloride (ethylamine-13C2,15N)	153-98-0 (unlabelled)	100 μg base/mL	methanol	1 mL
10864.10-1MG	Serotonin-13C2,15N hydrochloride (ethylamine-13C2,15N)	153-98-0 (unlabelled)	neat	neat	1 mg
10864.10-5MG	Serotonin-13C2,15N hydrochloride (ethylamine-13C2,15N)	153-98-0 (unlabelled)	neat	neat	5 mg
12010.9-100MG	(±)-Vanillomandelic acid (VMA, HMMA)	55-10-7	neat	neat	100 mg
10982.9-100-ME	(±)-Vanillomandelic acid-d3 (VMA-d3, HMMA-d3)	74495-70-8	100 μg/mL	methanol	1 mL
10982.9-K-ME	(±)-Vanillomandelic acid-d3 (VMA-d3, HMMA-d3)	74495-70-8	1000 μg/mL	methanol	1 mL
10982.9-10MG	(±)-Vanillomandelic acid-d3 (VMA-d3, HMMA-d3)	74495-70-8	neat	neat	10 mg
10982.9-50MG	(±)-Vanillomandelic acid-d3 (VMA-d3, HMMA-d3)	74495-70-8	neat	neat	50 mg

Part No.	Description	Cas No.
Tart No.	Description	Cas ivo.
Component part	Catecholamine Mix 1 3 Compounds at 1000 µg base/mL in methanol	
11646.1	(±)-Metanephrine hydrochloride	[881-95-8]
11647.9	(±)-Normetanephrine hydrochloride	[1011-74-1]
11650.9	3-Methoxytyramine hydrochloride	[1477-68-5]
S-4904-K-ME	1 x 1 mL ampoule	
S-4904-K-MEx5	5 x 1 mL ampoules	

Part No.	Description	Cas No.
Component part	Catecholamine Mix 2 6 Compounds at 1000 µg base/mL in methanol	
11646.1	(±)-Metanephrine hydrochloride	[881-95-8]
11647.9	(±)-Normetanephrine hydrochloride	[1011-74-1]
11648.9	(±)-Epinephrine hydrochloride	[329-63-5]
11649.8	(±)-Norepinephrine hydrochloride	[55-27-6]
11650.9	3-Methoxytyramine hydrochloride	[1477-68-5]
11651.8	Dopamine	[51-61-6]
S-4905-K-ME	1 x 1 mL ampoule	
S-4905-K-MEx5	5 x 1 mL ampoules	

For ordering and information about prices and delivery in your country, please contact your local distributor:



Your quality is our business

Chiron AS | Stiklestadveien 1 | N-7041 | Trondheim | Norway





